Experimental drug offered to one patient fighting transplant complications
NCT ID NCT05544032
Summary
This is an expanded access program that allows one patient with chronic graft-versus-host disease (GVHD) to receive the investigational drug axatilimab outside of a formal clinical trial. The program requires special approvals from the company, ethics committees, and regulatory authorities. It aims to provide potential treatment to a single individual who may benefit from this medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VS. HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.